At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALZN Alzamend Neuro, Inc
Closed 11-21 16:00:00 EST
1.30
-0.01
-0.76%
盘后1.30
+0.000.00%
19:52 EST
High1.32
Low1.27
Vol139.17K
Open1.29
D1 Closing1.31
Amplitude3.82%
Mkt Cap5.82M
Tradable Cap5.65M
Total Shares4.48M
T/O180.77K
T/O Rate3.20%
Tradable Shares4.35M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Alzamend Neuro announces full data set from nonclinical AL001 study
Alzamend Neuro Announces Full Data Set From Its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures Between Al001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
BRIEF-Alzamend Neuro Announces Full Data Set From Phase Iia Multiple Ascending Dose Clinical Trial For Al001 Treatment Of Dementia Related To Alzheimer’S
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.